1. Scrip
  2. >>Focus On Asia
  3. >>China

Pharma Execs: China Slowly Returning To Growth But Uncertainty Remains

MNC Q4 Highlights

 
• By Brian Yang and Dexter Jie Yan

Just how dynamic is the China market for multinationals? AstraZeneca is seeing growth returning while Pfizer is finding it challenging to estimate Paxlovid demand, Sanofi is encouraged by volume gains and GSK is predicting a "sizeable" rebound. Top executives from Novartis and Roche also shed light on other challenges facing global pharma firms in the world's second-largest pharma market as they reported annual results.

Poring Studio/Shutterstock.com
MNCs see China growth returning but COVID impact lingers • Source: Shutterstock

In recent annual earnings calls, executives from multiple multinational pharma firms shared varying views on the operating environment and growth prospects in China, a market that remains dynamic but challenging following the government's abrupt dismantling of strict "COVID Zero" policies.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

Arbele Leverages Rights As It Drugs Proprietary CDH17 Target

 
• By Dexter Jie Yan

Arbele has emerged as a global leader in the Cadherin 17 area, not only in clinical progress but also for its “secret recipe” for application in T-cell engagers, its CEO tells Scrip.

Henlius In David Versus Goliath Race With Pfizer For First PD-L1 ADC

 
• By Dexter Jie Yan

While Henlius Biotech’s PD-L1-targeting antibody-drug conjugate HLX43 is struggling to catch up with Pfizer’s PF-08046054, the global frontrunner in the space, a key differentiation of the China-originated asset could lie in PD-L1-negative patients.

Will China’s Retaliatory Tariffs Galvanize Manufacturing Onshoring?

 
• By Dexter Jie Yan

China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.

New Data Strengthen Case For RemeGen’s Telitacicept In gMG

 
• By Dexter Jie Yan

Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.

More from Focus On Asia

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

Henlius In David Versus Goliath Race With Pfizer For First PD-L1 ADC

 
• By Dexter Jie Yan

While Henlius Biotech’s PD-L1-targeting antibody-drug conjugate HLX43 is struggling to catch up with Pfizer’s PF-08046054, the global frontrunner in the space, a key differentiation of the China-originated asset could lie in PD-L1-negative patients.

US-China Tariff War Pressures Pharma’s Complex Supply Chain

 
• By Lisa Takagi

Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, Scrip hears.